chevron_leftBack
As of 8 June 2026, Enliven Therapeutics, Inc. has a market cap of $2.54B USD, ranking #6065 globally and #1556 in the United States.
It ranks #484 in the Healthcare sector, and #86 in the Biotechnology industry.
Key Stats
Market Cap
$2.54BUSD
Enterprise Value
$2.06BUSD
EBITDA (TTM)
-$119.4MUSD
Net Income (TTM)
-$103.69MUSD
PB Ratio
5.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Richard Fair
open_in_new
Employees
60
Founded
2016
IPO
12 Mar 2020
Website
enliventherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.4% | -8.3% | 8.3% | 66% | 95% | 122% |
News
Loading...
ELVN Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ELVN
Enliven Therapeutics Inc
ISIN: US29337E1029
Shares Out.:
Shares Outstanding:
60.905M1
Shares Float:
46.949M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
42.40 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
7K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
6K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
989%
|
-
|
|
NYSE: IQV
|
$26.3B
937%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
887%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
615%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$48.08B
2K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.48B
2K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$43.01B
2K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.72B
2K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$27.89B
1K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
913%
|
-
|
chevron_leftBack